CN202196058U - Medicine absorption instrument - Google Patents
Medicine absorption instrument Download PDFInfo
- Publication number
- CN202196058U CN202196058U CN 201120353850 CN201120353850U CN202196058U CN 202196058 U CN202196058 U CN 202196058U CN 201120353850 CN201120353850 CN 201120353850 CN 201120353850 U CN201120353850 U CN 201120353850U CN 202196058 U CN202196058 U CN 202196058U
- Authority
- CN
- China
- Prior art keywords
- absorption
- drug
- pond
- absorption cell
- intestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000010521 absorption reaction Methods 0.000 title claims abstract description 156
- 239000003814 drug Substances 0.000 title claims abstract description 113
- 229940079593 drug Drugs 0.000 title claims abstract description 90
- 230000000968 intestinal effect Effects 0.000 claims abstract description 108
- 239000007788 liquid Substances 0.000 claims abstract description 74
- 239000002699 waste material Substances 0.000 claims abstract description 19
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 12
- 239000001301 oxygen Substances 0.000 claims abstract description 12
- 239000012530 fluid Substances 0.000 claims description 34
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 29
- 230000002496 gastric effect Effects 0.000 claims description 11
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 abstract description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000013016 damping Methods 0.000 description 7
- 239000011664 nicotinic acid Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- DQVGWYCSZNMBDT-UHFFFAOYSA-L O.[Na+].[Cl-].[Na+].NCC(=O)O.[Cl-] Chemical compound O.[Na+].[Cl-].[Na+].NCC(=O)O.[Cl-] DQVGWYCSZNMBDT-UHFFFAOYSA-L 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000031891 intestinal absorption Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002572 peristaltic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000006174 pH buffer Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- FTKRHGWQEGWHAG-UHFFFAOYSA-L O.[K+].[Cl-].[Na+].[Cl-] Chemical compound O.[K+].[Cl-].[Na+].[Cl-] FTKRHGWQEGWHAG-UHFFFAOYSA-L 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- BUKHSQBUKZIMLB-UHFFFAOYSA-L potassium;sodium;dichloride Chemical compound [Na+].[Cl-].[Cl-].[K+] BUKHSQBUKZIMLB-UHFFFAOYSA-L 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Images
Landscapes
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
The utility model relates to a drug absorption instrument. The technical problem to be solved by the utility model is how to simulate the release-absorption condition of the medicine more accurately and efficiently. To the above technical problem, the utility model provides a drug absorption appearance, include: the device comprises a constant temperature system, an oxygen supply system, an intestinal liquid pool, a drug release pool, a pH regulator, at least one absorption pool, a liquid collecting pool and a waste liquid pool; wherein the constant temperature system is connected to intestines liquid bath and medicine release pond, intestines liquid bath and medicine release pond all are connected to the absorption cell, and oxygen system is connected to every absorption cell, sets up at least one intestines pipe mounting in the absorption cell, installs the intestines pipe on the intestines pipe mounting, and the absorption cell is connected to liquid collecting tank and waste liquid pond, and the pH regulator sets up in the upper reaches of absorption cell for adjust the pH value of the liquid in the absorption cell of pH regulator low reaches.
Description
Technical field
The utility model relates to a kind of drug-absorption system, more specifically relates to a kind of drug absorption appearance.
Background technology
Oral formulations is a kind of common formulation; The prerequisite of oral drugs performance drug effect is that medicine is through discharging; Got into by gastrointestinal absorption and to bring into play pharmacological action (except the medicine that directly plays a role at intestines and stomach) in the body, estimating drug, absorbing is the crucial content of oral formulations.For release and the absorbing state of medicine in intestines and stomach (for example, enteron aisle) is simulated, some bionic systems have been developed in the prior art now.For example, referring to Li Ziqiang etc. medicine stripping/absorption bionic system research tanshin polyphenolic acid B sustained release tablets release rule. drug evaluation research .2010 the 33rd the 5th phase of volume of October. the 367th page.
There are some shortcomings in bionic system of the prior art.
At first, medicine discharges in intestines and stomach, absorbs is a continuously dynamic process, but existing bionic system is static, efficiently and accurately the absorbing state of aids drug in enteron aisle.
Secondly; The pH value of gastric juice, intestinal juice is the continually varying process in the intestines and stomach; Intestinal juice pH also changes in the different enteron aisles; PH changes the influence greatly that is absorbed with to medicine, but the absorbing environmental of bionic system of the prior art is single, can not aids drug absorption under the different pH value environment in enteron aisle.
At last, bionic system of the prior art is lower for the absorption efficiency of medicine, carries out the time that simulated experiment needs labor.
The information that is disclosed in the utility model background technology part only is intended to deepen the understanding to the utility model general background technology, does not admit or hint in any form that this information constitutes to be prior art known in those skilled in the art and should not be regarded as.
The utility model content
In view of the shortcoming of above-mentioned prior art, the utility model technical matters to be solved is, develops a kind of drug absorption appearance, and this instrument can be simulated the release-absorbing state of medicine in human body or animal body more efficiently and accurately.The utility model another technical matters to be solved is, develops a kind of drug absorption appearance, and this instrument can be simulated the release-absorbing state of medicine in human body or animal body more efficiently.
In order to achieve the above object, the utility model provides a kind of drug absorption appearance, comprising: constant temperature system, oxygen system, intestinal juice pond, drug pond, pH-meter, at least one absorption cell, collecting tank, waste liquid pool; Wherein said constant temperature system is connected to said intestinal juice pond and said drug pond; Said intestinal juice pond and said drug pond all are connected to said absorption cell; Said oxygen system is connected to each absorption cell; At least one intestinal tube fixture is set in said absorption cell, on said intestinal tube fixture, mammal intestinal tube or biological filter membrane is installed, said absorption cell is connected to said collecting tank and said waste liquid pool; Said pH-meter is arranged at the upper reaches of said absorption cell, is used for the pH value of the liquid of the said absorption cell in said pH-meter downstream is regulated.
Said at least one absorption cell comprises two or more absorption cells that are linked in sequence.
Intestinal tube and said collecting tank in said intestinal juice pond, the said absorption cell form first liquid flow path, and tyrode flows in said first liquid flow path; Said drug pond, said absorption cell and said waste liquid pool form second liquid flow path, and the simulated gastric fluid of drug or simulated intestinal fluid flow in said second liquid flow path.The outside surface of said intestinal tube is the drug absorption surface.
Said intestinal juice pond, said absorption cell and said collecting tank form first liquid flow path, and tyrode flows in said first liquid flow path; Intestinal tube and said waste liquid pool in said drug pond, the said absorption cell form second liquid flow path, and the simulated gastric fluid of drug or simulated intestinal fluid flow in said second liquid flow path.The inside surface of said intestinal tube is the drug absorption surface.
In said intestinal juice pond and/or said drug pond, stirrer is set, in said drug pond, the medicine carrying basket is set.
Said drug absorption appearance also comprises flow controller, and said flow controller is arranged at the upper reaches of said absorption cell, is used for the fluid flow that gets into said absorption cell is controlled.
Said collecting tank is connected to analytical instrument, thereby makes said analytical instrument to analyze the liquid in the said collecting tank.
Downstream at each pH-meter are provided with valve.
The beneficial effect of the utility model is: through flow controller and at least one absorption cell are set, can simulate the release-absorbing state of medicine in human body or animal body more exactly.Through at least one intestinal tube is set, can improve simulation precision, save experimental period.Thereby the utility model is selected for the exploitation of pharmaceutical dosage form, all has higher-value for the evaluation of medicine itself or its active principle.
Be used to explain that through Figure of description and with accompanying drawing the embodiment of some principle of the utility model, further feature that the utility model had and advantage will become clear or be able to explain more particularly.
Description of drawings
Fig. 1 is the synoptic diagram according to first embodiment of the drug absorption appearance of the utility model.
Fig. 2 is the synoptic diagram according to second embodiment of the drug absorption appearance of the utility model.
Fig. 3 is the structural representation according to the intestinal tube fixture of the drug absorption appearance of the utility model.
Fig. 4 is the structural representation according to the pH-meter of the drug absorption appearance of the utility model.
Description of reference numerals:
1 drug pond
2 intestinal juice ponds
3 absorption cells
4 absorption cells
5 absorption cells
6 absorption cells
7 waste liquid pools
8 collecting tanks
9 oxygen systems
10 flow controllers
11 pH-meters
12 intestinal tube fixtures
13 stirrers
14 medicine carrying baskets
15 constant temperature systems
31 Z type pins
32 intestinal tubes
41 pH buffer pools
42 flow controllers
43 regulating reservoirs.
Each characteristic that it should be understood that the utility model shown in the accompanying drawing possibly adopt the mode of simplifying to represent to a certain extent, and be not necessarily in strict accordance with scale.Identical Reference numeral is in the accompanying drawings represented the identical or equivalent part of the utility model.
Embodiment
Below, with the embodiment that specifies the utility model, the example is presented in accompanying drawing and the following description.Though will combine exemplary embodiment to describe the utility model, be to be understood that this description do not really want to be limited to this exemplary embodiment to the utility model.On the contrary, the utility model will not only cover this exemplary embodiment, but also cover various replacements, that change, equivalence with other embodiment, it can be included in the spirit and scope of the utility model that accompanying claims limits.
First embodiment
Fig. 1 has shown first embodiment of the utility model.Wherein, the drug absorption appearance comprises: constant temperature system 15, oxygen system 9, intestinal juice pond 2, drug pond 1, flow controller 10, pH-meter 11, absorption cell 3-6, intestinal tube fixture 12, collecting tank 8, waste liquid pool 7, stirrer 13 and medicine carrying basket 14.Connecting tube between intestinal juice pond, drug pond, pH-meter, absorption cell, collecting tank, the waste liquid pool all is a double layer jacket structure, and these connecting tubes adopt pmma material.
In the embodiment shown in fig. 1; The drug absorption appearance comprises 4 absorption cells of series connection; Be from upstream to downstream (in Fig. 1 for from left to right) according to the direction of liquid flow and be respectively first absorption cell 3, second absorption cell 4, the 3rd absorption cell 5 and the 4th absorption cell 6, be furnished with flow controller and pH-meter between each absorption cell and its next-door neighbour's the absorption cell.The downstream of each pH-meter are provided with valve, are used for opening or closing as required flow channel.In the drug pond, be provided with stirrer and medicine carrying basket 14.Between intestinal juice pond and the absorption cell, between drug pond and absorption cell and at the upper reaches of collecting tank flow controller is being set respectively.
In the present embodiment; Flow controller adopts the form of peristaltic pump; Be used for the fluid flow that gets into absorption cell and collecting tank is controlled, make that the absorption apparatus in the present embodiment has the effect of simulation intestines peristalsis, thereby further strengthened the bionical effect of the utility model.In the present embodiment, stirrer adopts the form of stirrer, is used to promote the dissolving and the release of medicine.In addition, in other embodiments, in the intestinal juice pond, also stirrer can be set.The medicine carrying basket is used for medicament-carried.In the present embodiment, owing to have a plurality of pH-meters, thus can in each absorption cell, produce different pH values, thus with the mode of multistage pH value continually varying intestinal environment is simulated.
According to the mobility status of different liquids, the drug absorption appearance of the utility model comprises two liquid flow paths.According to the direction of liquid flow, first liquid flow path begins from the intestinal juice pond, through the intestinal tube in flow controller, each absorption cell; Come collecting tank; And second liquid flow path begins from the drug pond, through flow controller, pH controller, through flow controller and the pH controller between each absorption cell and each absorption cell; Pass through flow controller again, come waste liquid pool.In other words, intestinal tube in intestinal juice pond, the absorption cell and collecting tank form first liquid flow path, and tyrode flows in first liquid flow path; Drug pond, absorption cell and waste liquid pool form second liquid flow path, and the simulated gastric fluid of drug or simulated intestinal fluid flow in second liquid flow path.At this moment, the outside surface of intestinal tube is the drug absorption surface, and this drug absorption surface is the intestinal tube villous surface.
Intestinal tube among first embodiment turns up, and the simulated intestinal fluid of drug flows outside intestinal tube in absorption cell, and tyrode flows in intestinal tube.
In the embodiment shown in fig. 1,1 intestinal tube fixture is set in each absorption cell, intestinal tube 32 is fixed on this intestinal tube fixture, forms the part of first liquid flow path.Fig. 3 has schematically shown the intestinal tube fixture according to the drug absorption appearance of the utility model.The two ends of intestinal tube 32 are fixed to a Z type pin 31 respectively, and an end that is not connected with intestinal tube 32 of Z type pin 31 is connected to absorption cell.
The effect of constant temperature system is to make that the temperature of system keeps constant, and for this drug absorption appearance is applied to simulate the situation of human body intestinal absorption environment, this constant temperature system remains on about 37 ℃ with system temperature, with anthropomorphic dummy's body temperature.Oxygen system is connected to each absorption cell, is used to absorption cell and supplies with oxygen.
In first embodiment of the utility model, the volume in intestinal juice pond, drug pond is 500ml, and absorption cell is a rectangular parallelepiped, and inside dimension is: 12 * 3 * 4cm (length * wide * height).
Fig. 4 has schematically shown the pH-meter according to the drug absorption appearance of the utility model.PH-meter comprises pH buffer pool 41, flow controller 42 and regulating reservoir 43.PH buffer pool 41 is deposited the pH damping fluid, and is connected to regulating reservoir 43 via flow controller 42, and regulating reservoir 43 is installed between two absorption cells or between the drug pond and first absorption cell, forms the part of the second liquid fluid passage.
The operation steps of drug-absorption experiment that the drug absorption appearance that utilizes the utility model carried out is described below.
1, reagent preparation:
Simulated gastric fluid: get the watery hydrochloric acid that concentration is 1mol/ml, thin up transfers to 1.5 with pH.Add the 1g pepsin in every 100ml liquid, mixing, for use with the aseptic filter filtration of 0.2um.
Simulated intestinal fluid: get potassium dihydrogen phosphate 6.8g and add water 500mL.Sodium hydroxide solution with 0.4% is regulated pH to 6.8; Other gets pancreatin 10g and adds water and make dissolving in right amount, after two liquid are mixed, adds water and is settled to 1000mL and gets final product.
1N NaOH (100ml): 4g NaOH is dissolved in the distilled water, and thin up is to 100ml.
1N HCl (100ml): the 8.333ml concentrated hydrochloric acid, thin up is to 100ml.
PH-meter 1 damping fluid preparation: adopt potassium chloride-sodium hydrate buffer solution compound method preparation, regulate pH to 13.0 with 1N NaOH and 1N HCl solution.
PH-meter 2 damping fluids preparation: adopt aminoacetic acid-sodium chloride-sodium hydrate buffer solution compound method preparation, regulate pH to 11.6 with 1N NaOH and 1N HCl solution.
PH-meter 3 damping fluids preparation: adopt aminoacetic acid-sodium chloride-sodium hydrate buffer solution compound method preparation, regulate pH to 11.6 with 1N NaOH and 1N HCl solution.
PH-meter 4 damping fluids preparation: adopt aminoacetic acid-sodium chloride-sodium hydrate buffer solution compound method preparation, regulate pH to 11.6 with 1N NaOH and 1N HCl solution.
Absorption cell 1 reagent preparation: prepare tyrode earlier, regulate pH to 6.0-6.5 with 1N NaOH and 1N HCl solution then.
Absorption cell 2 reagent preparation: prepare tyrode earlier, regulate pH to 6.5-6.8 with 1N NaOH and 1N HCl solution then.
Absorption cell 3 reagent preparation: prepare tyrode earlier, regulate pH to 6.8-7.1 with 1N NaOH and 1N HCl solution then.
Absorption cell 4 reagent preparation: prepare tyrode earlier, regulate pH to 7.1-8.0 with 1N NaOH and 1N HCl solution then.
Tyrode: following reagent by said mixed, with the pure water dissolving, is transferred pH to 7.2-7.4 with 1N NaOH and 1N HCl.
| Reagent | NaCl | KCl | NaCO 3 | NaH 2PO 4 | MgCl 2 | CaCl 2 | ?Glu |
| Proportioning g/L | 8.0 | 0.28 | 1.0 | 0.05 | 0.1 | 0.2 | 1 |
The pH damping fluid:
Each several part pH value:
| Simulated gastric fluid | Simulated intestinal fluid | Tyrode | Absorption cell 1 | Absorption cell 2 | Absorption cell 3 | Absorption cell 4 | |
| The pH value | 1.5 | 6.8 | 7.2-7.4 | 6.0-6.5 | 6.5-6.8 | 6.8-7.1 | 7.1-8.0 |
2, preparation intestinal segment:
After the rat of fasting 12h was weighed before the experiment, disconnected cervical vertebra was put to death, and cuts off skin and muscle respectively along ventrimeson and hunter's line.Take out small intestine rapidly, begin to be that from the following 10cm of stomach pylorus jejunal segment, every interval 10cm intercepting 10cm are an experiment jejunal segment downwards, get 3 experiment jejunal segments; Beginning upwards to get 10cm from the above 5cm of ileocaecal sphineter is an experiment ileal segment, gets an experiment ileal segment.The intestinal tube of cutting is put into 0 ℃ of tyrode, removes intestinal tube and attend remnant tissue, with the tyrode flushing till do not have an intestinal contents.Silicone tube one end is inserted intestinal tube, carefully with the intestinal tube upset, with 0 ℃ of tyrode flushing inside surface.
3, drug-absorption test:
3.1 preheating:
Add tyrode 100mL in the intestinal juice pond before the experiment, add simulated gastric fluid or simulated intestinal fluid 400mL in the drug pond; Each absorption cell adds the reagent 100ml for preparing accordingly; Each pH-meter adds the pH damping fluid for preparing accordingly.
Open constant temperature system, constant temperature system is set to 37 ± 0.5 ℃; Aerating oxygen; Preheating 30min.
3.2 intestinal tube is fixed: the intestinal tube two ends after will overturning, are fixed in the absorption cell on the intestinal tube fixture with the silk thread ligation.
3.3 drug-absorption test: in the drug pond, add 1 of aspirin ordinary tablet; Start peristaltic pump and pH value regulator immediately, make in the intestinal tube with intestinal tube outer respectively with the flowing of suitable flow, then in different time points at intestinal absorption liquid pool sampling 0.1mL; Cross the 0.45um miillpore filter; Sample introduction 10ul injects HPLC and measures, and obtains the release-absorption curve of the different time points of aspirin ordinary tablet.
Medicine adds in the drug pond.
3.4 open peristaltic pump, medicine pumps in intestinal tube and the absorption cell with constant rate of speed in intestinal juice pond and the medicine dissolving tank, simulation intestinal absorption process 2 hours.
3.5 finishing the back, experiment collects solution in the collecting tank.
In addition, collecting tank is connected to analytical instrument, thereby makes said analytical instrument to analyze the liquid in the said collecting tank, thereby can estimate the drug absorption situation.
In the present embodiment, analytical instrument is high performance liquid chromatograph (HPLC or HPLC-MS), and this instrument is known to those skilled in the art, repeats no more at this.
Second embodiment
Fig. 2 has shown second embodiment of the utility model, has wherein schematically shown three absorption cells.Compare with first embodiment, the difference of second embodiment that shows among Fig. 2 is that also intestinal tube fixture and upward fixing intestinal tube thereof are installed on second fluid passage.That is to say that in a second embodiment, first liquid flow path begins from the intestinal juice pond; Through flow controller,, pass through flow controller again through each absorption cell; Come collecting tank, and second liquid flow path begins from the drug pond, through flow controller, pH controller; Through intestinal tube and flow controller between each absorption cell and the pH controller in each absorption cell, come waste liquid pool.In other words, intestinal juice pond, absorption cell and collecting tank form first liquid flow path, and tyrode flows in first liquid flow path; Intestinal tube in drug pond, the absorption cell and waste liquid pool form second liquid flow path, and the simulated gastric fluid of drug or simulated intestinal fluid flow in second liquid flow path.At this moment, the inside surface of intestinal tube is the drug absorption surface, and this drug absorption surface is the intestinal tube villous surface.
Intestinal tube among second embodiment is upset not, and the simulated intestinal fluid of drug flows in intestinal tube, and tyrode flows outside intestinal tube in absorption cell.The experiment back is analyzed the liquid in the collecting tank, can estimate the drug absorption situation.
The 3rd embodiment
The 3rd embodiment according to the utility model only comprises an absorption cell.Constant temperature system is connected to intestinal juice pond and drug pond; Intestinal juice pond and drug pond all are connected to absorption cell, and oxygen system is connected to this absorption cell, comprise two intestinal tube fixtures that intestinal tube is installed that parallel connection is provided with in this absorption cell; Absorption cell is connected to collecting tank and waste liquid pool; PH-meter is arranged at the upper reaches of absorption cell, and collecting tank is connected to analytical instrument, thereby makes analytical instrument to analyze the liquid in the collecting tank.
Two intestinal tubes and collecting tank in intestinal juice pond, the absorption cell form first liquid flow path, and tyrode flows in first liquid flow path; Drug pond, absorption cell and waste liquid pool form second liquid flow path, and the simulated gastric fluid of drug or simulated intestinal fluid flow in second liquid flow path.At this moment, intestinal tube turns up, and promptly the outside surface of intestinal tube is the drug absorption surface.
Combine accompanying drawing that the utility model has been carried out exemplary description above; Obviously the concrete realization of the utility model does not receive the restriction of aforesaid way; As long as adopted method design of the utility model and the various improvement that technical scheme is carried out; Perhaps the design of the utility model and technical scheme are directly applied to other occasions, all within the protection domain of the utility model without improving.
For example, the drug absorption appearance of the utility model can comprise the flow controller and the pH controller of one or more absorption cells and respective numbers, that is to say, the quantity of absorption cell is not equal to 4 situation and is also contained in the scope of the utility model.
And for example, one or more intestinal tubes and corresponding intestinal tube fixture can be set in any absorption cell, that is to say, intestinal tube quantity is not equal to 1 situation and is also contained in the scope of the utility model in any absorption cell.For example, in first absorption cell, can the intestinal tube fixture that two or more are equipped with intestinal tube be set parallel connection, thereby can effectively increase the intestinal tube absorption area, improve absorption efficiency, save experimental period.
In addition, the utility model also can adopt the rat intestinal tube that artificial intestinal tube uses in replacing testing.For example, can use the film (biological membrane) of the biologically active of any synthetic.
Claims (10)
1. a drug absorption appearance is characterized in that, said drug absorption appearance comprises: constant temperature system, oxygen system, intestinal juice pond, drug pond, pH-meter, at least one absorption cell, collecting tank, waste liquid pool;
Wherein said constant temperature system is connected to said intestinal juice pond and said drug pond; Said intestinal juice pond and said drug pond all are connected to said absorption cell; Said oxygen system is connected to each absorption cell; At least one intestinal tube fixture is set in said absorption cell, on said intestinal tube fixture, mammal intestinal tube or biological filter membrane is installed, said absorption cell is connected to said collecting tank and said waste liquid pool; Said pH-meter is arranged at the upper reaches of said absorption cell, is used for the pH value of the liquid of the said absorption cell in said pH-meter downstream is regulated.
2. drug absorption appearance according to claim 1 is characterized in that, said at least one absorption cell comprises two or more absorption cells that are linked in sequence.
3. drug absorption appearance according to claim 1 is characterized in that, intestinal tube and said collecting tank in said intestinal juice pond, the said absorption cell form first liquid flow path, and tyrode flows in said first liquid flow path; Said drug pond, said absorption cell and said waste liquid pool form second liquid flow path, and the simulated gastric fluid of drug or simulated intestinal fluid flow in said second liquid flow path.
4. drug absorption appearance according to claim 1 is characterized in that, said intestinal juice pond, said absorption cell and said collecting tank form first liquid flow path, and tyrode flows in said first liquid flow path; Intestinal tube and said waste liquid pool in said drug pond, the said absorption cell form second liquid flow path, and the simulated gastric fluid of drug or simulated intestinal fluid flow in said second liquid flow path.
5. drug absorption appearance according to claim 3 is characterized in that, the outside surface of said intestinal tube is the drug absorption surface.
6. drug absorption appearance according to claim 4 is characterized in that, the inside surface of said intestinal tube is the drug absorption surface.
7. drug absorption appearance according to claim 1 is characterized in that, in said intestinal juice pond and/or said drug pond, stirrer is set, and in said drug pond, the medicine carrying basket is set.
8. drug absorption appearance according to claim 1 is characterized in that, said drug absorption appearance also comprises flow controller, and said flow controller is arranged at the upper reaches of said absorption cell, is used for the fluid flow that gets into said absorption cell is controlled.
9. drug absorption appearance according to claim 1 is characterized in that said collecting tank is connected to analytical instrument, thereby makes said analytical instrument to analyze the liquid in the said collecting tank.
10. drug absorption appearance according to claim 1 is characterized in that, in the downstream of each pH-meter valve is set.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201120353850 CN202196058U (en) | 2011-09-20 | 2011-09-20 | Medicine absorption instrument |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201120353850 CN202196058U (en) | 2011-09-20 | 2011-09-20 | Medicine absorption instrument |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN202196058U true CN202196058U (en) | 2012-04-18 |
Family
ID=45950961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201120353850 Expired - Lifetime CN202196058U (en) | 2011-09-20 | 2011-09-20 | Medicine absorption instrument |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN202196058U (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102721796A (en) * | 2012-06-27 | 2012-10-10 | 浙江省中医药研究院 | Experimental device for simulating local drug release behavior of medicine and application thereof |
| CN103018413A (en) * | 2011-09-20 | 2013-04-03 | 中国中医科学院中药研究所 | Drug absorption apparatus |
| CN111122802A (en) * | 2019-12-30 | 2020-05-08 | 广东嘉博制药有限公司 | Method for measuring release curve of propofol fat emulsion injection |
-
2011
- 2011-09-20 CN CN 201120353850 patent/CN202196058U/en not_active Expired - Lifetime
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103018413A (en) * | 2011-09-20 | 2013-04-03 | 中国中医科学院中药研究所 | Drug absorption apparatus |
| CN103018413B (en) * | 2011-09-20 | 2015-03-18 | 中国中医科学院中药研究所 | Drug absorption apparatus |
| CN102721796A (en) * | 2012-06-27 | 2012-10-10 | 浙江省中医药研究院 | Experimental device for simulating local drug release behavior of medicine and application thereof |
| CN111122802A (en) * | 2019-12-30 | 2020-05-08 | 广东嘉博制药有限公司 | Method for measuring release curve of propofol fat emulsion injection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103476920B (en) | Apparatuses for and methods of processing cells and related structures | |
| EP3119870B1 (en) | Dynamic multi organ plate | |
| CN102313795B (en) | Intelligent numerical control bionic drug dissolubility tester | |
| CN202196058U (en) | Medicine absorption instrument | |
| CN105170205A (en) | Bionic chip constructed based on micro-fluidic chip technology | |
| Matsumoto et al. | Ingested delphinidin-3-rutinoside is primarily excreted to urine as the intact form and to bile as the methylated form in rats | |
| CN210863698U (en) | Differential dissolving device for simulating internal dissolving and absorption of oral medicinal preparation | |
| CN108211032B (en) | Combined bioartificial liver support system | |
| CN108430529A (en) | system and method for extracorporeal blood treatment | |
| CN104826676B (en) | Micro-fluidic chip, system and application thereof | |
| CN103877631A (en) | Bioartificial liver system | |
| CN100486586C (en) | Imature bitter orange total flavone and its preparing method for its preparation and quality control method | |
| CN105842407A (en) | Vertical type animal gastrointestinal bionic digester | |
| CN105505775A (en) | Extracorporeal liver support system | |
| CN111356919A (en) | Auxiliary device for dissolution test | |
| CN202033355U (en) | Bionic system device for in-vivo and in-vitro relevant evaluation of medicine solid preparation body | |
| CN103018413B (en) | Drug absorption apparatus | |
| Amidon et al. | Predicted absorption rates with simultaneous bulk fluid flow in the intestinal tract | |
| CN111435134A (en) | Gastrointestinal dynamic simulation device | |
| Singh et al. | Coaxial cell printing of a human glomerular model: an in vitro glomerular filtration barrier and its pathophysiology | |
| CN105435700A (en) | Device and method for blending nutrient solution in nutrition department | |
| CN202256305U (en) | Intelligent numerical-control tester for dissolution rate of bionic medicines | |
| CN209894783U (en) | Gastrointestinal dynamic simulation device | |
| Ramírez-Fernández et al. | Design and development of a dual-flow bioreactor mimicking intestinal peristalsis and permeability in epithelial tissue barriers for drug transport assessment | |
| Kong et al. | Analysis of aerobic granulation trigger driving mechanism under different organic substrate diffusibility based on microfluidic system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| AV01 | Patent right actively abandoned |
Granted publication date: 20120418 Effective date of abandoning: 20150318 |
|
| AV01 | Patent right actively abandoned |
Granted publication date: 20120418 Effective date of abandoning: 20150318 |
|
| RGAV | Abandon patent right to avoid regrant |